Atlas Trials

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

Clinical trial NCT00035022 · COMPLETED

Trial details

NCT number
NCT00035022
Sponsor
BioCryst Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Leukemia, LymphocyticLymphoma
Start date
2001-08-01
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.